Public Portfolio Companies

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company (NYSE, ATNM) developing ARC’s or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium’s lead application for our ARC’s is targeted conditioning, which is intended to selectively kill patient’s cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, CAR-T and other cell therapies. With their ARC approach, they seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently. Actinium’s lead product candidate, Iomab-B is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.

Total Money Raised (as of June 2015): $61,000,000

Amesite is a high-tech artificial intelligence company (Nasdaq, AMST) developing a cloud-based platform for course design that rapidly provides customized, high performance and scalable online products for schools and businesses. Amesite was founded in 2017 and based in Ann Arbor, Michigan. Inspired by the $1.52 Trillion of United States college debt, Amesite’s mission is to cost-effectively and conveniently deliver to learners online. The company uses artificial intelligence to power the platform that promotes engagement and improves learning. They offer three course packages: Amesite college; focusing on transferrable college-level credits, Amesite professional; focusing on continuing education in the workplace, and Amesite life; focusing on personal education and enrichment.

Total Money Raised (as of September 2020): $28,000,000

The BioSig Technologies logo

BioSig Technologies is a medtech company (Nasdaq, BSGM) developing a proprietary biomedical signal processing platform called PURE EP System to provide high fidelity electrocardiographic and intracardiac signals with the objective of assisting physicians making a better clinical decision during electrophysiology procedures in patients with abnormal heart rates and rhythms. PURE EP System has received 510(k) clearance in 2018 with EU CE mark submitted. Future goal of the PURE EP System is to improve catheter ablation treatments for patients with potentially deadly arrhythmias, atrial fibrillation and ventricular tachycardia. BSGM has long collaboration with multiple medical institutions, including Mayo Clinic. BSGM is conducting a clinical trial with topline result readout expected in 2020. PURE EP System has been installed in several medical institutions and BSGM plans to expand the installation base in 2020 and beyond. Overall, BSGM is an emerging player with a well differentiated technology of the fast-growing bioelectronic medicine market.

Total Money Raised (as of February 2020): $29,000,000

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company (Nasdaq, HOTH) focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth owns the exclusive rights to develop the BioLexa Platform for all indications in humans. The BioLexa Platform is a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups by preventing the formation of infectious biofilms and the resulting clogging of sweat ducts. It is the first product candidate intended to prevent the symptom-triggering flare-ups rather than simply treating symptoms after they occur.

Total Money Raised (as of March 2020): $17,000,000

Relmada Therapeutics is a clinical stage, publicly traded specialty pharmaceutical company (Nasdaq, RLMD), focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. Intent is to develop and commercialize product candidates for CNS conditions with high unmet needs. Their strategy focuses on developing REL-1017 (dextromethadone) in depression, Rett syndrome, and other ophthalmology and CNS diseases where REL-1017 mechanism of action could have a major therapeutic impact.

Total Money Raised (as of October 2014): $52,000,000